Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Pfizer Inc (PFE) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Pfizer Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.93, while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Pfizer Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDXPFE
52-Week High
$49.91$28.56
52-Week Low
$47.57$23.60
Market Cap
$154.18B
Volume
29,869,932
Sector
Health
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX, the Vanguard Total International Bond ETF, trades at $47.95, up 0.13% on the day. The technical outlook is neutral overall, with bearish moving averages and neutral oscillators. Recent corporate actions include scheduled dividend payments in 2026. Market sentiment is influenced by global bond yield fluctuations and institutional trading activity, as seen with Apella Capital reducing its stake and Archer Investment Management increasing its holdings.

The outlook for BNDX is tied to international bond market dynamics, with opportunities from investor demand for yield but risks from inflation data and geopolitical tensions affecting Treasury yields. Key risks include interest rate uncertainty and oil price volatility, which could pressure bond performance. Institutional interest remains mixed, reflecting cautious optimism amid macroeconomic headwinds.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE